Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy

Antonella Mangraviti, Betty Tyler, Henry Brem

Research output: Contribution to journalArticlepeer-review

Abstract

The advent of interstitial chemotherapy has significantly increased therapeutic options for patients with malignant glioma. Interstitial chemotherapy can deliver high concentrations of chemotherapeutic agents, directly at the site of the brain tumor while bypassing systemic toxicities. Gliadel, a locally implanted polymer that releases the alkylating agent carmustine, given alone and in combination with various other antitumor and resistance modifying therapies, has significantly increased the median survival for patients with malignant glioma. Convection enhanced delivery, a technique used to directly infuse drugs into brain tissue, has shown promise for the delivery of immunotoxins, monoclonal antibodies, and chemotherapeutic agents. Preclinical studies include delivery of chemotherapeutic and immunomodulating agents by polymer and microchips. Interstitial chemotherapy was shown to maximize local efficacy and is an important strategy for the efficacy of any multimodal approach.

Original languageEnglish (US)
Pages (from-to)S78-S84
JournalSurgical Neurology International
Volume6
Issue number2
DOIs
StatePublished - Jan 1 2015

Keywords

  • Carmustine
  • Gliadel <sup>®</sup>
  • Glioblastoma multiforme
  • Interstitial chemotherapy
  • Malignant glioma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy'. Together they form a unique fingerprint.

Cite this